Richard Hobbs
University of Oxford
H-index: 114
Europe-United Kingdom
Top articles of Richard Hobbs
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Periodontal diseases and cardiovascular diseases, diabetes, and respiratory diseases: Summary of the consensus report by the European Federation of Periodontology and WONCA Europe | David Herrera Mariano Sanz Lior Shapira Carlos Brotons Iain Chapple | 2024/12/31 | |
Disparities in COVID-19 Mortality Amongst the Immunosuppressed: A Systematic Review and Meta-analysis for Enhanced Disease Surveillance | Meredith Leston Willam Elson Jose M Ordóñez-Mena Debasish Kar Heather Whitaker | 2024/1/30 | |
Diagnostic accuracy of a point-of-care antigen test for SARS-CoV-2 and influenza in a primary care population (RAPTOR-C19) | Clinical Microbiology and Infection | Thomas R Fanshawe Sharon Tonner Philip J Turner Jade Cogdale Margaret Glogowska | 2024/3/1 |
Randomised controlled trial of population screening for atrial fibrillation in people aged 70 years and over to reduce stroke: protocol for the SAFER trial | BMJ open | Jonathan Mant Rakesh N Modi Andrew Dymond Natalie Armstrong Jenni Burt | 2024/4/1 |
Reliability of single-lead electrocardiogram interpretation to detect atrial fibrillation: insights from the SAFER Feasibility Study | medRxiv | Katie Hibbitt James Brimicombe Martin R Cowie Andrew Dymond Ben Freedman | 2024/1/30 |
The feasibility of population screening for paroxysmal atrial fibrillation using handheld ECGs | Europace | Jonathan Mant Rakesh N Modi Peter Charlton Andrew Dymond Efthalia Massou | 2024/2/27 |
Estimating Vitamin K antagonist anticoagulation benefit in people with atrial fibrillation accounting for competing risks: evidence from 12 randomized trials | Circulation: Cardiovascular Quality and Outcomes | Sachin J Shah Carl van Walraven Sun Young Jeon John Boscardin FD Richard Hobbs | 2024/4 |
Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England | Nature Communications | Isobel L Ward Chris Robertson Utkarsh Agrawal Lynsey Patterson Declan T Bradley | 2024/1/16 |
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial | Infectious Diseases and Therapy | FD Richard Hobbs Hugh Montgomery Francisco Padilla Jesus Abraham Simón-Campos Douglas Arbetter | 2024/2/25 |
Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes … | British Journal of General Practice | May Ee Png Victoria Harris Jenna Grabey Nigel David Hart Bhautesh Dinesh Jani | 2024/1/12 |
AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: The RAVEN cohort study | Journal of Infection | Wilhelmine Meeraus Mark Joy Mario Ouwens Kathryn S Taylor Sudhir Venkatesan | 2024/4/1 |
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients | Nature communications | Joseph F Standing Laura Buggiotti Jose Afonso Guerra-Assuncao Maximillian Woodall Samuel Ellis | 2024/2/23 |
Protocol: Randomised controlled trial of population screening for atrial fibrillation in people aged 70 years and over to reduce stroke: protocol for the SAFER trial | BMJ Open | Jonathan Mant Rakesh N Modi Andrew Dymond Natalie Armstrong Jenni Burt | 2024 |
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short-and longer-term outcomes | Journal of Infection | Gail Hayward Ly-Mee Yu Paul Little Oghenekome Gbinigie Milensu Shanyinde | 2024/4/1 |
Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in … | The Lancet Regional Health–Europe | Stuart Bedston Fatima Almaghrabi Lynsey Patterson Utkarsh Agrawal Lana Woolford | 2024/2/1 |
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic | The Lancet Infectious Diseases | Simon de Lusignan FD Richard Hobbs Aziz Sheikh | 2024/1/1 |
Preferences for Multi-Cancer Early Detection (MCED) in primary care: Discrete-choice experiments in four stakeholder groups in England | John Buckell Nomalanga Millicent Madyiwa Apostolos Tsiachristas Philip Turner Gail Hayward | 2024/3/19 | |
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study | The Lancet Oncology | Brian D Nicholson Jason Oke Pradeep S Virdee Dean A Harris Catherine O'Doherty | 2023/7/1 |
Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel … | The Lancet Regional Health–Europe | Mark Joy Utkarsh Agrawal Xuejuan Fan Chris Robertson Sneha N Anand | 2023/9/1 |
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials | Thrombosis research | Stefano Barco Saverio Virdone Andrea Götschi Walter Ageno Juan I Arcelus | 2023/10/1 |
Co-Authors
